Strong Monthly Breakout, Higher High–Higher Low Pattern and Positive Momentum Indicators Signal Further Upside for India's Largest Pharma Stock

Shares of Sun Pharmaceutical Industries Ltd. continue to remain in focus after Bajaj Broking reaffirmed its bullish stance on the stock, citing a combination of strong technical indicators, improving price structure and sustained buying momentum. The brokerage has maintained its 'Buy' recommendation with a target price of ₹2,180, indicating a potential upside of nearly 11% from current market levels.

Sun Pharma has been one of the standout performers in the pharmaceutical sector over the past few months, consistently outperforming the benchmark indices. Although the stock traded marginally lower during Wednesday's session amid profit booking, analysts believe the broader long-term trend remains firmly positive.

The recommendation comes at a time when the pharmaceutical sector continues to attract investor interest, supported by resilient domestic demand, steady export growth and increasing focus on specialty medicines.

Sun Pharma Continues to Outperform the Broader Market

Sun Pharma has delivered healthy returns during the current financial year, outperforming the benchmark Nifty 50 index.

Performance Comparison

The stock has maintained its upward trajectory over the last four months and is currently trading close to its all-time high.

On Wednesday, Sun Pharma was trading around ₹1,965–₹1,978, while its 52-week high stands at ₹1,993.

The stock's consistent outperformance reflects sustained institutional buying and positive sentiment towards the pharmaceutical sector.

Bajaj Broking Maintains High Conviction 'Buy' Call

In its latest High Conviction Margin Trading Funding (MTF) Picks report dated July 28, 2026, Bajaj Broking reiterated its positive outlook on Sun Pharma.

The brokerage believes the stock has entered a fresh phase of long-term strength after completing a multi-month consolidation.

According to the report, the stock possesses a favourable technical structure that could support a gradual move towards ₹2,180 over the coming quarters.

The brokerage's recommendation is based on four major technical developments that indicate improving long-term momentum.

1. Breakout Above a 21-Month Consolidation Range

The primary reason behind Bajaj Broking's bullish outlook is the stock's decisive breakout above a prolonged consolidation zone.

For nearly 21 months, Sun Pharma traded within a broad range of approximately ₹1,583 to ₹1,960.

The recent breakout above this range is considered a significant technical development because it signals renewed buying interest after an extended period of sideways movement.

According to technical analysts, such breakouts often mark the beginning of a fresh upward trend supported by stronger investor participation.

The breakout also indicates that market participants are willing to accumulate the stock at higher price levels.

2. Strong Relative Strength Signals Institutional Buying

Another important observation made by Bajaj Broking is the stock's impressive recovery from its previous correction.

Sun Pharma retraced its entire 16-month decline in just five months, demonstrating exceptional relative strength.

Analysts believe such rapid recoveries generally indicate:

• Strong institutional participation

• Healthy demand from long-term investors

• Positive market sentiment

• Confidence in the company's long-term growth prospects

The speed of the recovery suggests buyers have remained active even at elevated valuations.

3. Structural Trend Reversal Supports Long-Term Bullish View

The brokerage believes the recent breakout also confirms a major structural trend reversal.

Instead of merely witnessing a temporary price rally, Sun Pharma has now established a stronger long-term technical base.

The stock has transitioned from a prolonged consolidation phase into a sustained upward trend.

This change in market structure significantly improves the probability of further appreciation over the medium and long term.

Analysts consider such structural reversals particularly important because they often attract additional institutional investment.

4. Higher High–Higher Low Formation Remains Intact

Sun Pharma continues to exhibit one of the strongest characteristics of a healthy bull market.

The stock has consistently formed:

• Higher highs

• Higher lows

This pattern reflects sustained buying pressure and indicates that investors continue purchasing the stock during every correction.

Technical analysts generally interpret this formation as confirmation that the primary trend remains upward.

As long as this pattern remains intact, the probability of further gains remains favourable.

Momentum Indicators Continue to Support the Rally

Apart from price action, momentum indicators are also supporting the bullish outlook.

Bajaj Broking highlighted that the 14-period Relative Strength Index (RSI) on the monthly chart has recently generated a fresh buy signal after crossing above its 9-period moving average.

A rising RSI generally reflects strengthening buying momentum and improving investor confidence.

Unlike sharp short-term spikes, a gradually rising monthly RSI often supports sustainable long-term trends.

Key Support Zone Identified

Despite trading near record levels, Bajaj Broking believes the stock has a well-defined support zone.

The brokerage expects the July low near ₹1,860 to serve as an important support level over the medium term.

Additionally, the entire consolidation base continues to remain above the 12-month Exponential Moving Average (EMA).

This indicates that the broader trend remains constructive even if the stock experiences temporary profit booking.

Holding above these support levels could pave the way for another leg of the rally.

Target of ₹2,180 Based on Fibonacci Projection

Bajaj Broking's target price of ₹2,180 is derived using Fibonacci extension analysis, a widely followed technical methodology.

The brokerage expects the stock to gradually move towards the 161.8% external retracement level of its previous decline.

Key Technical Levels

A sustained breakout above its previous record high could strengthen the bullish momentum further.

Pharmaceutical Sector Continues to Attract Investors

The pharmaceutical sector has remained one of the better-performing segments of the Indian equity market during FY27.

Several factors continue to support the sector:

• Stable domestic healthcare demand

• Increasing pharmaceutical exports

• Expansion of specialty medicine portfolios

• Higher healthcare spending

• Strong product pipelines

• Growing demand from regulated international markets

Large-cap pharmaceutical companies such as Sun Pharma continue to benefit from these structural industry trends.

Technical Strength Reflects Long-Term Investor Confidence

Market experts believe Sun Pharma's recent price behaviour reflects sustained confidence among institutional investors.

The stock's ability to remain close to record highs despite intermittent profit booking indicates continued accumulation by long-term market participants.

Combined with improving technical indicators, the overall chart structure remains favourable from a medium- to long-term perspective.

Factors Investors Should Monitor

Going ahead, investors will closely watch:

• Sustainability of the breakout above ₹1,960

• Q1 FY27 earnings performance

• Domestic formulations growth

• Performance of the specialty medicines business

• Export market developments

• Overall pharmaceutical sector sentiment

• Institutional buying activity

• Movement around lifetime high levels

These factors are expected to determine whether the stock can achieve the brokerage's projected target over the coming quarters.

Market Outlook

Sun Pharma continues to display strong technical momentum supported by a decisive breakout, improving market structure and sustained buying interest. While short-term volatility cannot be ruled out as the stock trades near record highs, the broader trend remains positive according to technical indicators. Going forward, earnings growth, sector performance and the stock's ability to sustain levels above key support zones are expected to remain the primary drivers of future price movement.